Bio-Rad Laboratories has broadened its collection of recombinant monoclonal anti-idiotypic antibodies, adding specificities for pertuzumab (Perjeta), guselkumab (Tremfya), canakinumab (Ilaris), belimumab (Benlysta), and the bispecific therapy emicizumab (Hemlibra). The company has also introduced a new Human IgM-FcSpyCatcher to its SpyCatcher reagent line. The expanded anti-biotherapeutic antibody range supports the creation of robust, reliable bioanalytical assays for pharmacokinetic (PK) and anti-drug-antibody (ADA) studies. These tools help researchers monitor therapeutic drug levels for both innovator and biosimilar products, including the five newly added drug targets. The Human IgM-FcSpyCatcher offers a novel way to rapidly generate pentameric and hexameric IgM formats at the protein level, enabling format switching without additional cloning. Fully compatible with Bio-Rad’s recombinant HuCAL antibodies, the reagent has been validated in ELISA, western blotting, and precipitation workflows. \"With 45 drug specificities and more than 250 monoclonal anti-idiotypic antibodies, Bio-Rad provides exceptional flexibility for developing highly selective and sensitive bioanalytical assays,\" said Hilary Mavor, Marketing Director, Life Science Group, Bio-Rad. \"The addition of the new SpyCatcher protein further enhances our ability to deliver innovative bioanalysis tools for both catalogue and custom antibody customers, advancing antibody drug discovery.\" All new antibodies and reagents are approved for in vitro research use. The anti-idiotypic antibodies are also cleared for use in commercial in vitro testing services, supporting preclinical and clinical drug development, biosimilar programs, and patient monitoring. More information online.

Expanded antibody and reagent portfolio for bioanalysis

Bio-Rad Laboratories has expanded its portfolio of recombinant monoclonal anti-idiotypic antibodies to include specificities for pertuzumab (Perjeta), guselkumab (Tremfya), canakinumab (Ilaris), belimumab (Benlysta), and emicizumab (Hemlibra). The company has also introduced a new Human IgM-FcSpyCatcher reagent to its SpyCatcher line, enabling rapid generation of pentameric and hexameric IgM formats without additional cloning. These tools support robust bioanalytical assays for pharmacokinetic and anti-drug-antibody studies, aiding in therapeutic drug level monitoring for innovator and biosimilar products. The new reagent is fully compatible with Bio-Rad’s recombinant HuCAL antibodies and has been validated in ELISA, western blotting, and precipitation workflows. The products are approved for in vitro research and commercial in vitro testing services, supporting preclinical and clinical development, biosimilar programs, and patient monitoring.